Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Australian Nanotechnology Companies Set to Revoltionize Drug Delivery

Abstract:
Interstitial NanoSystems and Quintain NanoSystems Spin Off From NanoVic

Australian Nanotechnology Companies Set to Revoltionize Drug Delivery

MELBOURNE, AUSTRALIA and BOSTON, MA | Posted on May 7th, 2007

Two Australian bio-nanotech companies are set to revolutionize the way that medicine is delivered. Victorian Premier Steve Bracks announced today at BIO 2007 in Boston that Nanotechnology Victoria Ltd (NanoVic) is launching Interstitial NanoSystems (Interstitial NS) and Quintain NanoSystems (Quintain NS) as independent companies. The NanoVic spin-offs are the result of a portfolio of projects and developments built around strategic investment of nearly A$14 million with over a dozen partners since 2004.

Interstitial NanoSystems

Interstitial NS is initially focusing on its pain-free insulin delivery patch for diabetes, while the first product for Quintain NS is a rapid clinical test for the detection of meningitis. "Both diseases have devastating effects on people around the world," said Mr. Bracks. "Any new product that makes it easier to test for a disease or to take a life-saving drug is welcomed." NanoVic is attending BIO 2007 and will have prototypes of a selection of these products on display.

Dr. Bob Irving, Director of Interstitial NS and Quintain NS said, "We are excited at the prospects of the two new companies, Interstitial NS and Quintain NS, commercializing the nanotechnology innovations in delivery and diagnostics, to provide better health outcomes with reduced costs to the community. These companies will help to consolidate the key skills, technologies and manufacturing abilities in areas of nanomedicine, where Australia and Victoria have strength."

The Interstitial NS transdermal delivery patch for insulin has already been tested on animals by the Victorian College of Pharmacy and is expected to begin pre-clinical trials in September. Interstitial NS is working with Melbourne-based company Catapult to produce a portable prototype device to enable self administration. The patches are manufactured by the Victorian company MiniFAB, while the nanostructured drugs are formulated by Eiffel Technology.

Interstitial NS will also commercialize a device for pulmonary delivery of nanoparticulate drugs. The portable personal inhaler uses Surface Acoustic Wave (SAW) technology, with Melbourne-based Charlwood Design designing the prototype pump. Pre-clinical trials are anticipated to start in January 2008. The transdermal delivery technology used by Interstitial NS has already been recognized as "prime technological innovation" by analysts Frost & Sullivan.

Quintain NanoSystems

Quintain NS has a number of products in the pipeline, initially focusing on a diagnostic test for the detection of meningitis. The test uses nanoparticle technology to provide a rapid color-based readout, avoiding lengthy bacterial culturing for identifying the bacteria. Also in development are a number of other diagnostic tools. Nanoparticle-based imaging reagents will enable early detection of disease states in humans. Nanoarray biochips will offer a cost effective method of detection for both salmonella and bovine mastitis, and enzyme biosensor probes are under development for the measurement of sulfite in food and beverages.

####

About NanoVic
Nanotechnology Victoria Ltd is the key organization for delivering nanotechnology research outcomes to Victorian industry. NanoVic has a membership of three universities; Monash, RMIT and Swinburne as research and technology providers, with financial backing from the State Government of Victoria.

For more information, please click here

Contacts:
Media Contact:
Michelle Linn
Linnden Communications
Office: 508-419-1555
Mobile: 774-696-3803

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

Nanometrics Announces Upcoming Investor Events July 22nd, 2014

Nanomedicine

Taking the guesswork out of cancer therapy: New molecular test kit predicts patientís survival and drug response August 1st, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Announcements

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Forceís 30-year plan seeks 'strategic agility' August 1st, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE